[{"data":1,"prerenderedAt":177},["ShallowReactive",2],{"drug-tirzepatide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":51,"warnings":61,"renal":69,"monitoring":70,"interactions":71,"review":72,"examples":75,"atc":76,"iran":78,"links":110,"populations":129,"usApproval":172},"tirzepatide",1,{"fa":7,"en":8},"تیرزپاتاید (تزریقی هفتگی)","Tirzepatide (weekly injection)","alimentary-metabolism",{"fa":11,"en":12},"آگونیست دوگانه GIP و GLP-1","Dual GIP\u002FGLP-1 receptor agonist",[14],{"name":15,"market":16},"Mounjaro","US",[18,19,20],"mounjaro","مونجارو","تیرزپاتاید",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"pen","injection","sc","Pen or vial 2.5–15 mg per dose",{"amount":5,"unit":28,"perUnit":29},"mg","application",[16],[32],{"source":33,"section":34},"fda-mounjaro","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":43,"unit":28,"dose":44,"refs":48},"t2d","type-2-diabetes",{"fa":40,"en":41},"دیابت نوع ۲ — هفته‌ای یک بار: شروع ۲٫۵ mg","Type 2 diabetes — once weekly: start 2.5 mg",{},"notCalculated",{"reason":45},{"fa":46,"en":47},"هفته‌ای یک بار زیرجلدی (نه روزانه). شروع ۲٫۵ mg؛ در صورت نیاز هر دست‌کم ۴ هفته ۲٫۵ mg افزایش. حداکثر: بزرگسال ۱۵ mg و کودک ۱۰ mg در هفته.","Once WEEKLY subcutaneous (not daily). Start 2.5 mg; increase by 2.5 mg after at least 4 weeks as needed. Max: adults 15 mg, children 10 mg weekly.",[49],{"source":33,"section":50},"2.1",[52],{"id":53,"severity":54,"text":55,"refs":58},"mtc","block",{"fa":56,"en":57},"سابقه شخصی یا خانوادگی کارسینوم مدولاری تیروئید یا MEN 2؛ حساسیت جدی.","Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity.",[59],{"source":33,"section":60},"4",[62],{"text":63,"refs":66},{"fa":64,"en":65},"هشدار جعبه‌ای: تومور سلول C تیروئید در جوندگان؛ در سابقه MTC یا MEN 2 ممنوع.","Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history.",[67],{"source":33,"section":68},"Boxed Warning",[],[],[],{"status":73,"reviewer":74,"date":74},"unverified",null,[],[77],"A10BX16",{"status":79,"forms":80,"refs":105},"registered",[81,85,89,93,97,101],{"code":82,"en":83,"fa":84},"53508","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 7.5 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۷٫۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":86,"en":87,"fa":88},"53506","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 2.5 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۲٫۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":90,"en":91,"fa":92},"53507","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 5 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":94,"en":95,"fa":96},"53590","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 10 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۱۰ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":98,"en":99,"fa":100},"53584","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 12.5 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۱۲٫۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",{"code":102,"en":103,"fa":104},"53592","TIRZEPATIDE INJECTION, SOLUTION SUBCUTANEOUS 15 mg\u002F0.5mL","فرآورده تزریقی تیرزپاتاید ۱۵ میلی‌گرم \u002F ۰٫۵ میلی‌لیتر",[106],{"source":107,"section":108,"url":109},"darooyab-generic","G-5545\u002FTirzepatide","https:\u002F\u002Fwww.darooyab.ir\u002FG-5545\u002FTirzepatide",[111,115,119,123,126],{"kind":112,"url":113,"label":114},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=215866","NDA215866",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","FDA Mounjaro",{"kind":120,"url":121,"label":122},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622044.html","Tirzepatide injection",{"kind":124,"url":125,"label":77},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BX16",{"kind":127,"url":109,"label":128},"darooyab","Tirzepatide",{"pregnancy":130,"lactation":139,"pediatric":147,"geriatric":155,"reproductive":164},{"level":131,"text":132,"quote":135,"refs":136},"caution",{"fa":133,"en":134},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.",[137],{"source":33,"section":138},"8.1",{"level":131,"text":140,"quote":143,"refs":144},{"fa":141,"en":142},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose ( see Data ).",[145],{"source":33,"section":146},"8.2",{"level":131,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established.",[153],{"source":33,"section":154},"8.4",{"level":156,"text":157,"quote":160,"refs":161},"ok",{"fa":158,"en":159},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness of MOUNJARO have been observed between patients 65 years of age and older and younger adult patients.",[162],{"source":33,"section":163},"8.5",{"level":131,"text":165,"quote":168,"refs":169},{"fa":166,"en":167},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying.",[170],{"source":33,"section":171},"8.3",{"kind":173,"refs":174,"id":114},"NDA",[175],{"source":33,"section":176},"SPL approval \u002F marketing category",1792111469902]